LXEO
Lexeo Therapeutics, Inc.
$4.21
-3.66%
$332.9M
No data for this timeframe.
Vol
Market Cap$332.9M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders8 funds
Inst. Value$50.5M
Inst. Activity7 buys / 0 sells
Insider Activity0B / 6S
Insider Net $-$427.6K
SEC Reports4
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0001907108·Prev Close $4.37
Recent Activity
May 20, 2026
SEC
Two LXEO insiders — CEO and COO — sold a combined $24K in open-market sales on the same day, 9 days after Q1 2026 earnin
CLUSTER — Impact 2/10
May 20, 2026
short_volume
Short Volume: LXEO — 91.4% short (0.8M / 0.9M)
Short: 799,209 | Exempt: 0 | TRF Vol: 874,254 | Short Ratio: 91.4% | Off-exchange volume (dark pool
May 18, 2026
Insider
Townsend Richard Nolan sold 3,342 shares
Chief Executive Officer @ $5.06 ($16.9K)
May 18, 2026
Insider
Otero Jose Manuel sold 1,302 shares
Chief Operating Officer @ $5.07 ($6.6K)
May 11, 2026
SEC
Lexeo Therapeutics reported Q1 2026 results with a net loss of $20.2M ($0.25 per share), narrowing from $32.7M ($0.99 pe
8-K — Impact 6/10
May 11, 2026
SEC
Lexeo Therapeutics reported Q1 2026 net loss of $0.25 per share, beating consensus estimates of -$0.30 by 16.7%, with re
PRESS-RELEASE — Impact 6/10
Apr 28, 2026
Insider
Sepp-Lorenzino Laura sold 50,000 shares
Director @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — ADD
3,894,310 shares ($38.7M)
Price Targets
$20.60
+385.8% upside
Strong Buy
Current $4.24
Low $12.00
Median $19.50
High $30.00
10 analysts
$12.00
$30.00
Analyst Ratings
8Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Jan 13, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Jan 13, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Dec 18, 2025 | Raymond James | INITIATE | Strong Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.28 ▲ +10.3% | $-0.32 — $-0.24 | 59% YoY | 6 |
| Next Q | $-0.31 ▲ +10.4% | $-0.39 — $-0.26 | 5% YoY | 8 |
| Current FY | $-1.14 ▲ +11.5% | $-1.28 — $-0.99 | 41% YoY | 6 |
| Next FY | $-1.31 ▲ +7.7% | $-1.77 — $-0.74 | -10% YoY | 8 |
Latest Reports
NEUTRAL
CLUSTER
2/10
Two LXEO insiders — CEO and COO — sold a combined $24K in open-market sales on the same day, 9 days after Q1 2026 earnin
May 20, 2026
BULLISH
8-K
6/10
Lexeo Therapeutics reported Q1 2026 results with a net loss of $20.2M ($0.25 per share), narrowing from $32.7M ($0.99 pe
May 11, 2026
BULLISH
Press
7/10
Lexeo Therapeutics reported financial results for Q4 and full year 2025, highlighted by a strong cash position of $246.6
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $38.7M | ADD |
| TWO SIGMA INVESTMENTS, LP | $4.0M | DOUBLED |
| RENAISSANCE TECHNOLOGIES LLC | $2.2M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.9M | ADD |
| BANK OF AMERICA CORP | $1.6M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Townsend Richard | SELL | $16.9K |
| May 18, 2026 | Otero Jose | SELL | $6.6K |
| Apr 28, 2026 | Sepp-Lorenzino Laura | A | $0.00 |
| Apr 6, 2026 | Townsend Richard | SELL | $313.1K |
| Mar 13, 2026 | Otero Jose | A | $15.7K |
8 institutional holders with $50.5M total value (5,089,452 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, RENAISSANCE. Net buying activity: 7 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,894,310 | $38.7M | 76.5% | ADD +74.9% |
| 2 | TWO SIGMA INVESTMENTS, LP | 400,567 | $4.0M | 7.9% | DOUBLED +372.6% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 217,772 | $2.2M | 4.3% | ADD +45.9% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 192,210 | $1.9M | 3.8% | ADD +81.7% |
| 5 | BANK OF AMERICA CORP /DE/ | 160,288 | $1.6M | 3.1% | DOUBLED +466.8% |
| 6 | MORGAN STANLEY | 140,181 | $1.4M | 2.8% | ADD +43.0% |
| 7 | WELLS FARGO & COMPANY/MN | 70,736 | $702.4K | 1.4% | DOUBLED +267.2% |
| 8 | FMR LLC | 13,388 | $132.9K | 0.3% | DOUBLED +392.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 2,226,290 | 3,894,310 | +74.9% | $38.7M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 84,763 | 400,567 | +372.6% | $4.0M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 149,300 | 217,772 | +45.9% | $2.2M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 105,760 | 192,210 | +81.7% | $1.9M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 28,279 | 160,288 | +466.8% | $1.6M | 2025-Q4 |
| MORGAN STANLEY | ADD | 98,057 | 140,181 | +43.0% | $1.4M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 19,262 | 70,736 | +267.2% | $702.4K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 106,200 | 149,300 | +40.6% | $991.4K | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 64,220 | 105,760 | +64.7% | $702.2K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 15,325 | 19,262 | +25.7% | $127.9K | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 1,099,285 | 2,002,866 | +82.2% | $8.1M | 2025-Q2 |
| UBS Group AG | DOUBLED | 32,082 | 271,904 | +747.5% | $1.1M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 20,300 | 106,200 | +423.2% | $426.9K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | ADD | 36,624 | 69,242 | +89.1% | $278.4K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 11,409 | 15,325 | +34.3% | $61.6K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 36,624 | — | $127.1K | 2025-Q1 |
| UBS Group AG | TRIM | 51,054 | 32,082 | -37.2% | $111.3K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 20,300 | — | $70.4K | 2025-Q1 |
| FMR LLC | DOUBLED | 2,003 | 9,864 | +392.5% | $34.2K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 241,828 | 74,828 | -69.1% | $492.4K | 2024-Q4 |
| UBS Group AG | DOUBLED | 11,112 | 51,054 | +359.4% | $335.9K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 7,442 | 11,156 | +49.9% | $73.4K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 12,663 | 241,828 | +1809.7% | $2.2M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 63,874 | — | $577.4K | 2024-Q3 |
5 unique insiders with 6 transactions. Net insider value: -$427.6K ($0.00 bought, $427.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Townsend Richard Nolan | Chief Executive Officer | SELL | 3,342 | $5.06 | $16.9K |
| May 18, 2026 | Otero Jose Manuel | Chief Operating Officer | SELL | 1,302 | $5.07 | $6.6K |
| Apr 28, 2026 | Sepp-Lorenzino Laura | Director | A | 50,000 | $0.00 | $0.00 |
| Apr 6, 2026 | Townsend Richard Nolan | Chief Executive Officer | SELL | 55,000 | $5.69 | $313.1K |
| Mar 13, 2026 | Otero Jose Manuel | Chief Operating Officer | A | 5,930 | $2.64 | $15.7K |
| Mar 13, 2026 | Townsend Richard Nolan | Chief Executive Officer | A | 2,623 | $2.64 | $6.9K |
| Feb 18, 2026 | Otero Jose Manuel | Chief Operating Officer | SELL | 3,016 | $6.40 | $19.3K |
| Feb 18, 2026 | Townsend Richard Nolan | Chief Executive Officer | SELL | 10,173 | $6.38 | $64.9K |
| Feb 13, 2026 | Bhalla Narinder Pal | Chief Medical Officer | A | 49,500 | $0.00 | $0.00 |
| Feb 13, 2026 | Bhalla Narinder Pal | Chief Medical Officer | A | 297,000 | $0.00 | $0.00 |
| Feb 4, 2026 | Otero Jose Manuel | Chief Operating Officer | A | 65,000 | $0.00 | $0.00 |
| Feb 4, 2026 | Otero Jose Manuel | Chief Operating Officer | A | 260,000 | $0.00 | $0.00 |
| Feb 4, 2026 | Townsend Richard Nolan | Chief Executive Officer | A | 161,665 | $0.00 | $0.00 |
| Feb 4, 2026 | Townsend Richard Nolan | Chief Executive Officer | A | 646,665 | $0.00 | $0.00 |
| Feb 4, 2026 | Tamayo Louis Edward | Chief Financial Officer | A | 44,665 | $0.00 | $0.00 |
| Feb 4, 2026 | Tamayo Louis Edward | Chief Financial Officer | A | 226,665 | $0.00 | $0.00 |
| Nov 18, 2025 | Otero Jose Manuel | Chief Operating Officer | SELL | 721 | $9.27 | $6.7K |
4 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.3/10.
NEUTRAL
CLUSTER
2/10
Two LXEO insiders — CEO and COO — sold a combined $24K in open-market sales on the same day, 9 days
May 20, 2026
BULLISH
8-K
6/10
Lexeo Therapeutics reported Q1 2026 results with a net loss of $20.2M ($0.25 per share), narrowing f
May 11, 2026
BULLISH
PRESS-RELEASE
6/10
Lexeo Therapeutics reported Q1 2026 net loss of $0.25 per share, beating consensus estimates of -$0.
May 11, 2026
BULLISH
8-K
7/10
Lexeo Therapeutics reported Q4 2025 financials with a narrow loss of $0.27 per share, beating consen
Apr 21, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 8 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$20.60 mean target
+385.8% upside
Strong Buy (3.00)
$12.00 Low
$30.00 High
| Metric | Value |
|---|---|
| Current Price | $4.24 |
| Target Low | $12.00 |
| Target Mean | $20.60 |
| Target Median | $19.50 |
| Target High | $30.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.28 | $-0.32 | $-0.24 | 59.1% | +10.3% | 3↑ 0↓ | $0.0B | 0.0% | 6 |
| Next Q 2026-09-30 |
$-0.31 | $-0.39 | $-0.26 | 5.4% | +10.4% | 7↑ 0↓ | $0.0B | 0.0% | 8 |
| Current FY 2026-12-31 |
$-1.14 | $-1.28 | $-0.99 | 41.1% | +11.5% | 3↑ 0↓ | $0.0B | 0.0% | 6 |
| Next FY 2027-12-31 |
$-1.31 | $-1.77 | $-0.74 | -10.5% | +7.7% | 4↑ 0↓ | $0.0B | 0.0% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.277 | |
| 7d ago | $-0.283 | +0.006 |
| 30d ago | $-0.308 | +0.032 |
| 60d ago | $-0.347 | +0.070 |
| 90d ago | $-0.347 | +0.070 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 13, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 13, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | Raymond James | INITIATE | — | Strong Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 7 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 8 | 8 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 8 | 8 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 8 | 8 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 8 | 8 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 8 | 8 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 20, 2026
short_volume
Short Volume: LXEO — 91.4% short (0.8M / 0.9M)
Short: 799,209 | Exempt: 0 | TRF Vol: 874,254 | Short Ratio: 91.4% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings
Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
1Q 2026 Earnings
May 11, 2026
earnings_calendar
LXEO Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
earnings_calendar
LXEO Q1 2026 Earnings Scheduled — 2026-05-07
Apr 27, 2026
routine
Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
ASGCT 2026 Abstracts
Mar 30, 2026
earnings
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Lexeo Earnings release
Mar 16, 2026
earnings_calendar
LXEO Q4 2025 Earnings Before Market Open — 2026-03-16
Mar 3, 2026
other
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference